FDA Approves Once-Daily Jentadueto XR (linagliptin and metformin hydrochloride extended-release) for Type 2 Diabetes

Posted on June 2, 2016September 11, 2016 by Vita

Ridgefield, Conn., and Indianapolis, May 31, 2016 – The U.S. Food and Drug Administration (FDA) has approved Jentadueto XR (linagliptin and metformin hydrochloride extended-release) tablets for the treatment of type 2 diabetes (T2D) in adults. Jentadueto XR, which is marketed by Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY), is the seventh new treatment[…]

Low salt intake may raise risk of heart attack, stroke, and death

Posted on May 21, 2016September 11, 2016 by Vita

A high salt intake has been linked to increased blood pressure and greater risk for heart problems. But according to new research, low salt intake may be just as harmful. Researchers suggest only people with high blood pressure who have a high salt intake should reduce their salt consumption. Published in The Lancet, the study[…]

ссылка